Serial #79085755
LIVE

Serial Number

79085755

Owner

BIONORICA SE

Attorney

Norman H. Zivin

Filing Date

Jun 26, 2010

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79085755 Trademark

Serial Number: 79085755 • Registration: 3972716

Serial #79085755 is a trademark filed by BIONORICA SE on June 26, 2010. The trademark is classified under Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

BIONORICA SE (41 trademarks)

KERSCHENSTEINERSTRAßE 11-15
NEUMARKT 92318 , DE

Entity Type: 94

Trademark Details

Filing Date

June 26, 2010

Registration Date

June 7, 2011

Published for Opposition

March 22, 2011

Cancellation Date

January 12, 2018

Goods & Services

Educational services, namely, providing classes and workshops in the field of health, health consciousness and health queries to medical practitioners, health specialists and/or patients, providing of training in particular providing information about education in the field of health, health consciousness and health queries for medical practitioners, health specialists and patients, also via the Internet

Pharmaceutical preparations for use in the treatment, cure, mitigation or prevention of gingivitis, halitosis, stomatitis, periodontitis, inflammation of the oral cavity and pharyngeal cavity, hypersensitivity of teeth, angina, atherosclerosis, bronchial asthma, circulatory disorders, constipation, diarrhea, heart failure, heart rhythm disorders, high blood pressure, indigestion, insomnia, migraine, motion sickness, nausea, peptic ulcers, vomiting, allergy, gynecological disorders affecting menstruation, sterility, menstrual syndromes, dysmenorrhoea, infertility, genital tract infections, pelvic inflammatory diseases, vaginal discomfort due to menopausal atrophic changes, anatomical abnormalities of the head, the extremities, chest, abdomen and organs, neoplasia, breast neoplasm, breast cancer, mastopathy, mastodynia, premenstrual syndrome, climacteric complaints, breast pain, blood conditions and disorders, blood circulation disorders, high blood pressure, hypertension, pulmonary diseases, heart rhythm disorders, heart failure, urological diseases, sexually transmitted diseases and inflammatory pelvic diseases, menopausal complaints due to therapeutically induced menopause, tamoxifen induced hot flashes of breast cancer survivors, climactic sleep disturbances, depressive moods, protection of the skeletal system, osteoporosis, central nervous system infections, brain diseases, central nervous system movement disorders, ocular mobility disorders, spinal cord diseases, psycho vegetative disorders, depressive syndrome, anxiety, nervous unrest, peripheral nervous system infections, peripheral nervous system movement disorders, nerve compression syndromes, neuritis, neuralgia and regional pain syndromes, diseases and disorders of the kidney, urological disorders, chronic infections of the bladder, cystitis, pyelonephritis, glomerulonephritis, interstitial nephritis, nephrolithiasis, cancer, urolith prophylaxis, dizziness, migraine, depression, inflammations of the upper and lower respiratory organs, sinuses, bronchitis, tonsillitis, arthritis, osteoarthritis, fever, cough, cold, Alzheimer's disease, infection of respiratory tract, infection of urinary tract, urinary obstruction, chronic venous insufficiency, prostate hyperplasia, muscle pains, soft tissue rheumatism, musculoskeletal disease, liver disease, hepatitis, cirrhosis of liver, periodontal diseases and dental caries; pharmaceutical preparations for use as an antidepressant, diuretic, hypnotic, sedative, analeptic, and tranquilizer; haemorrhoidal ointment, laxative, nasal decongestant capsules, nasal spray preparations, non-narcotic analgesics, throat lozenges; medicinal preparations in tablet form, namely, menstruation circulation regulating tablets; pharmaceutical preparations, namely, for hormone regulation and hormone replacement; pharmaceutical preparations for sensory organs, namely, for use in ophthalmology, otolaryngology and dermatology; pharmaceutical preparations for regulation and strengthening of the immune system, pharmaceutical preparations for treating of and providing temporary relief for occasional minor irritation, pain, sore mouth, sore gums, sore throat, pain associated with canker sores, pain due to minor irritation or injury of the mouth and gums, pain due to minor dental procedures, pain due to minor irritations caused by dentures or orthodontic appliances, sore gums due to teething in infants and children four months of age and older; pharmaceutical products, namely, medicated dental, gum and mouth washes, medicated dental, gum and mouth rinse, medicated toothpastes, medicated oral-care gels, medicated dental gels, medicated lozenges, cough lozenges, medicated chewing gum, medicated gels and fluids in the nature of medicated balms, medicated dental tapes, medicated dental ribbons, medicated dental polish; pharmaceutical preparations for dental purposes, namely, plaque disclosing reagents, periodontal diagnostic reagents for medical purposes for detecting derivatives from periodontal bacteria and caries, diagnostic reagents for detecting derivatives from caries-causing bacteria and medicines for the prevention and treatment of periodontal diseases, dental caries, canker sores, cold sores, mucositis and oral and tongue cancers; sanitary preparations for medical use; sanitary preparations for hygiene, namely, antiseptics, oral antiseptics, disinfectants for health purposes; medicated sanitary preparations for the treatment, cleaning and protection of the skin; dietary supplements in the form of tablets, drops, capsules, extract preparations, balms or in liquid form, containing plant extracts; dietetic substances adapted for medical use, namely, dietetic foods, dietetic beverages, dietetic sugar, dietetic food supplements; medical and surgical plasters; plant extracts for pharmaceutical purposes and plant extracts used as dietetic substances adapted for medical use; nutritional additives for medical purposes, namely, dietary and nutritional supplements for human consumption; medicinal oils; vitamin and mineral supplements; food and food supplements, namely, herbal teas for medicinal purposes and medicinal teas; medicinal herbs; materials for dressings, namely, gauze and bandages; all purpose disinfectants

Medical services; hygienic and beauty care for human beings; medical consultancy, consultancy in the fields of pharmaceutical advice and health, also via the Internet

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Aug 2, 2024 NREP
NEW REPRESENTATIVE AT IB RECEIVED
May 8, 2024 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Sep 11, 2023 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Apr 22, 2023 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Feb 22, 2023 NREP
INTERNATIONAL REGISTRATION RENEWED
Jul 17, 2020 RNWL
FINAL DECISION TRANSACTION PROCESSED BY IB
Dec 6, 2019 FINO
NEW REPRESENTATIVE AT IB RECEIVED
Dec 4, 2018 NREP
TOTAL INVALIDATION PROCESSED BY THE IB
Oct 19, 2018 INNT
REFUSAL PROCESSED BY IB
Sep 28, 2018 RFNT
GENERIC MADRID TRANSACTION SENT TO IB
Sep 17, 2018 XXSS
GENERIC MADRID TRANSACTION CREATED
Sep 17, 2018 XXCR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Sep 12, 2018 INTR
CANCELLED SECTION 71
Jan 12, 2018 C71T
NEW REPRESENTATIVE AT IB RECEIVED
Jun 12, 2014 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 26, 2013 FINO
NEW REPRESENTATIVE AT IB RECEIVED
Jun 6, 2012 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Apr 22, 2012 NREP
FINAL DISPOSITION NOTICE SENT TO IB
Nov 1, 2011 FICS
FINAL DISPOSITION PROCESSED
Nov 1, 2011 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 7, 2011 FICR
REGISTERED-PRINCIPAL REGISTER
Jun 7, 2011 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 22, 2011 NPUB
PUBLISHED FOR OPPOSITION
Mar 22, 2011 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 3, 2011 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 3, 2011 OP2R
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 17, 2011 PREV
ASSIGNED TO LIE
Feb 11, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 18, 2011 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 18, 2011 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 18, 2011 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 18, 2011 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 18, 2011 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 11, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 11, 2011 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 11, 2011 TROA
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 19, 2010 ADCH
REFUSAL PROCESSED BY IB
Nov 1, 2010 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 5, 2010 RFCS
REFUSAL PROCESSED BY MPU
Oct 5, 2010 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 5, 2010 RFCR
NON-FINAL ACTION WRITTEN
Oct 4, 2010 CNRT
ASSIGNED TO EXAMINER
Oct 4, 2010 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 7, 2010 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 3, 2010 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Sep 2, 2010 REPR